Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05791604

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

The Safety and Effectiveness Study of Prebiotics and Probiotics in the Intervention of Obesity in Children With Prader-Willi Syndrome

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Children's Hospital of Fudan University · Academic / Other
Sex
All
Age
3 Years – 10 Years
Healthy volunteers
Not accepted

Summary

Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.

Detailed description

Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. Morbid obesity and related complications caused by hyperappetite are the most common causes of poor prognosis and death in PWS. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. At present, more and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children. Participants will be divided into three groups, receiving probiotics, probiotics+probiotics or placebo treatment, and observe the changes in body weight, the structure of gut microbiota and metabolic level.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTprobiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GGTake probiotics, 2g each time, twice a day, for 12 weeks
DIETARY_SUPPLEMENTPrebiotics with galactomannan and oligofructoseTake probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks

Timeline

Start date
2023-04-01
Primary completion
2026-03-31
Completion
2026-07-31
First posted
2023-03-30
Last updated
2026-03-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05791604. Inclusion in this directory is not an endorsement.